Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2579)
All Articles published online
|
Oct 28, 2009 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Forde KA, Law C, O’Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15(40): 5020-5027 [PMID: 19859994 DOI: 10.3748/wjg.15.5020] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i40/5020.htm |
| Number | Citing Articles |
| 1 |
George Koutsoudakis, Xavier Forns, Sofía Pérez-del-Pulgar. Biología molecular aplicada del virus de la hepatitis C. Gastroenterología y Hepatología 2013; 36(4): 280 doi: 10.1016/j.gastrohep.2012.11.005
|
| 2 |
Marion Peyrou, Sophie Clément, Christiane Maier, Lucie Bourgoin, Emilie Branche, Stéphanie Conzelmann, Vincent Kaddai, Michelangelo Foti, Francesco Negro. PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. Journal of Hepatology 2013; 59(3): 420 doi: 10.1016/j.jhep.2013.04.012
|
| 3 |
G. Grammatikos, H. Farnik, D. Bon, A. Böhlig, T. Bader, T. Berg, S. Zeuzem, E. Herrmann. The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis. Journal of Viral Hepatitis 2014; 21(8): 533 doi: 10.1111/jvh.12274
|
| 4 |
V. Carreño. Review article: management of chronic hepatitis C in patients with contraindications to anti‐viral therapy. Alimentary Pharmacology & Therapeutics 2014; 39(2): 148 doi: 10.1111/apt.12562
|
| 5 |
Francisco J. Zapatero-Belinchón, Rina Ötjengerdes, Julie Sheldon, Benjamin Schulte, Belén Carriquí-Madroñal, Graham Brogden, Laura M. Arroyo-Fernández, Florian W. R. Vondran, Benjamin Maasoumy, Thomas von Hahn, Gisa Gerold. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells 2021; 10(7): 1626 doi: 10.3390/cells10071626
|
| 6 |
Stephanie Pollock, Norica Branza Nichita, Annette Böhmer, Cristina Radulescu, Raymond A. Dwek, Nicole Zitzmann. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proceedings of the National Academy of Sciences 2010; 107(40): 17176 doi: 10.1073/pnas.1009445107
|
| 7 |
Margaret F. Bassendine, David A. Sheridan, Daniel J. Felmlee, Simon H. Bridge, Geoffrey L Toms, R. Dermot G. Neely. HCV and the hepatic lipid pathway as a potential treatment target. Journal of Hepatology 2011; 55(6): 1428 doi: 10.1016/j.jhep.2011.06.004
|
| 8 |
David A. Sheridan, R. Dermot G. Neely, Margaret F. Bassendine. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clinics and Research in Hepatology and Gastroenterology 2013; 37(1): 10 doi: 10.1016/j.clinre.2012.07.002
|
| 9 |
Ching-Sheng Hsu, Wei-Liang Liu, Qisheng Li, Brianna Lowey, Laura Hertz, You-Chen Chao, T. Jake Liang, Ding-Shinn Chen, Jia-Horng Kao. Hepatitis C virus genotypes 1–3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. Journal of the Formosan Medical Association 2020; 119(9): 1382 doi: 10.1016/j.jfma.2020.03.018
|
| 10 |
Martin Janicko, Sylvia Drazilova, Daniel Pella, Jan Fedacko, Peter Jarcuska. Pleiotropic effects of statins in the diseases of the liver. World Journal of Gastroenterology 2016; 22(27): 6201-6213 doi: 10.3748/wjg.v22.i27.6201
|
| 11 |
Ben Verpaalen, Johan Neyts, Leen Delang. Are statins a viable option for the treatment of infections with the hepatitis C virus?. Antiviral Research 2014; 105: 92 doi: 10.1016/j.antiviral.2014.02.020
|
| 12 |
Paul Targett-Adams, Steeve Boulant, Mark W. Douglas, John McLauchlan. Lipid Metabolism and HCV Infection. Viruses 2010; 2(5): 1195 doi: 10.3390/v2051195
|
| 13 |
Cristin Constantin Vere, Costin Teodor Streba, Liliana Streba, Ion Rogoveanu. Statins in the Treatment of Hepatitis C. Hepatitis Monthly 2012; 12(6): 369 doi: 10.5812/hepatmon.5998
|
| 14 |
Daniel Felmlee, Mohamed Hafirassou, Mathieu Lefevre, Thomas Baumert, Catherine Schuster. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. Viruses 2013; 5(5): 1292 doi: 10.3390/v5051292
|
| 15 |
Takasuke Fukuhara, Chikako Ono, Francesc Puig-Basagoiti, Yoshiharu Matsuura. Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus. Trends in Microbiology 2015; 23(10): 618 doi: 10.1016/j.tim.2015.07.007
|
| 16 |
Scott A. Read, Enoch Tay, Mahsa Shahidi, Jacob George, Mark W. Douglas. Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology 2014; 95(9): 1900 doi: 10.1099/vir.0.065300-0
|
| 17 |
David H. Van Thiel, Magdalena George, Bashar M. Attar, Giuliano Ramadori, Niculae Ion-Nedelcu. Plasma Triglyceride Levels May Modulate Hepatitis C Viral Replication. Digestive Diseases and Sciences 2014; 59(4): 881 doi: 10.1007/s10620-014-3079-5
|
| 18 |
Qianqian Zhu, Na Li, Qunying Han, Pingping Zhang, Cuiling Yang, Xiaoyan Zeng, Yanping Chen, Yi Lv, Xi Liu, Zhengwen Liu. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis. Antiviral Research 2013; 98(3): 373 doi: 10.1016/j.antiviral.2013.04.009
|
| 19 |
Naveen Kumar, Shalini Sharma, Ram Kumar, Bhupendra N. Tripathi, Sanjay Barua, Hinh Ly, Barry T. Rouse. Host-Directed Antiviral Therapy. Clinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00168-19
|
| 20 |
Andrea Wuestenberg, Janine Kah, Katrin Singethan, Hüseyin Sirma, Amelie Dorothea Keller, Sergio René Perez Rosal, Jörg Schrader, Christine Loscher, Tassilo Volz, Ralf Bartenschlager, Volker Lohmann, Ulrike Protzer, Maura Dandri, Ansgar W. Lohse, Gisa Tiegs, Gabriele Sass, Anna Alisi. Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. PLoS ONE 2014; 9(5): e96533 doi: 10.1371/journal.pone.0096533
|
| 21 |
Steven W. Johnson, Dorothea K. Thompson, Brianne Raccor. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current Infectious Disease Reports 2017; 19(6) doi: 10.1007/s11908-017-0578-5
|
| 22 |
F. Angelico, M. Del Ben. Towards predicting the therapeutic response in patients with hepatitis C: authors’ reply. Alimentary Pharmacology & Therapeutics 2010; 31(2): 340 doi: 10.1111/j.1365-2036.2009.04188.x
|
| 23 |
Myung‐Ho Kim, Mi‐Young Kim, Shadi Salloum, Tongqi Qian, Lai Ping Wong, Min Xu, Yoojin Lee, Stuti G. Shroff, Ruslan I. Sadreyev, Kathleen E. Corey, Thomas F. Baumert, Yujin Hoshida, Raymond T. Chung. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatology Communications 2022; 6(9): 2581 doi: 10.1002/hep4.1991
|
| 24 |
Belén Carriquí-Madroñal, Lisa Lasswitz, Thomas von Hahn, Gisa Gerold. Genetic and pharmacological perturbation of hepatitis-C virus entry. Current Opinion in Virology 2023; 62: 101362 doi: 10.1016/j.coviro.2023.101362
|
| 25 |
Kyung-Soo Chang, Hyun-Jung Jo. HMG CoA Reductase Inhibitors Inhibit HCV RNA Replication of HCV Genotype 1b but Not 2a. Journal of Bacteriology and Virology 2011; 41(2): 99 doi: 10.4167/jbv.2011.41.2.99
|
| 26 |
Koen Vercauteren, Ahmed Atef Mesalam, Geert Leroux-Roels, Philip Meuleman. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World Journal of Gastroenterology 2014; 20(43): 15975-15991 doi: 10.3748/wjg.v20.i43.15975
|
| 27 |
Waqas Gulzar, Zafar Niaz, Sami Ullah Mumtaz, Somia Iqtadar, Tayyeba Komal, Sajid AbaidUllah. Efficacy of Atorvastatin Plus Pegylated Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin Alone in Chronic Hepatitis C Patients with Genotype-3a. Pakistan BioMedical Journal 2019; 2(1) doi: 10.52229/pbmj.v2i1.28
|
| 28 |
Akira Honda, Yasushi Matsuzaki. Cholesterol and chronic hepatitis C virus infection. Hepatology Research 2011; 41(8): 697 doi: 10.1111/j.1872-034X.2011.00838.x
|
| 29 |
David A. Sheridan, Simon H. Bridge, Mary M. E. Crossey, Daniel J. Felmlee, Fiona I. Fenwick, Howard C. Thomas, R. Dermot G. Neely, Simon D. Taylor‐Robinson, Margaret F. Bassendine. Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial. Liver International 2014; 34(5): 737 doi: 10.1111/liv.12316
|
| 30 |
Kai Lin, Philippe Gallay. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Research 2013; 99(1): 68 doi: 10.1016/j.antiviral.2013.03.020
|
| 31 |
Armita M. Gorabi, Nasim Kiaie, Vanessa Bianconi, Tannaz Jamialahmadi, Khalid Al-Rasadi, Thomas P. Johnston, Matteo Pirro, Amirhossein Sahebkar. Antiviral effects of statins. Progress in Lipid Research 2020; 79: 101054 doi: 10.1016/j.plipres.2020.101054
|
| 32 |
Carlos Noe Farfan-Morales, Carlos Daniel Cordero-Rivera, José Manuel Reyes-Ruiz, Arianna M. Hurtado-Monzón, Juan Fidel Osuna-Ramos, Arely M. González-González, Luis Adrián De Jesús-González, Selvin Noé Palacios-Rápalo, Rosa María del Ángel. Anti-flavivirus Properties of Lipid-Lowering Drugs. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.749770
|
| 33 |
Hans L. Tillmann, John G. McHutchison. Zakim and Boyer's Hepatology. 2012; : 564 doi: 10.1016/B978-1-4377-0881-3.00031-0
|
| 34 |
L. Milazzo, I. Caramma, C. Mazzali, M. Cesari, M. Olivetti, M. Galli, S. Antinori. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Journal of Antimicrobial Chemotherapy 2010; 65(4): 735 doi: 10.1093/jac/dkq002
|
| 35 |
Valerie A. Villareal, Mary A. Rodgers, Deirdre A. Costello, Priscilla L. Yang. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antiviral Research 2015; 124: 110 doi: 10.1016/j.antiviral.2015.10.013
|
| 36 |
Adeel A. Butt, Peng Yan, Hector Bonilla, Abdul‐Badi Abou‐Samra, Obaid S. Shaikh, Tracey G. Simon, Raymond T. Chung, Shari S. Rogal. Effect of addition of statins to antiviral therapy in hepatitis C virus–infected persons: Results from ERCHIVES. Hepatology 2015; 62(2): 365 doi: 10.1002/hep.27835
|
| 37 |
Prashant Pandya, Fadi Rzouq, Olurinde Oni. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. Clinics and Research in Hepatology and Gastroenterology 2015; 39(5): 555 doi: 10.1016/j.clinre.2015.02.005
|